INO Financial Facts
Loss from investment in affiliated entity: -958.14KNet loss/ (gain) attributable to non-controlling interest: 0
See Full Income Statement
Total current liabilities: 41.37M
Non-controlling interest: 96.27K
See Full Balance Sheet
Inovio Pharma (INO) Earnings
|
Expand Research on INO
| Next EPS Date | 5/8/24 | EPS Growth Rate | -625.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +55.3% | Revenue Growth Rate | +490.9% |
| Average % Move 1-Wk after EPS | -0.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/1/22 |  |
Q421 | -$1.45 | -$0.32 | -$1.13 | $1.77M | $2.84M | N/A |  | | Details |
| 3/13/24 | Q423 | N/A | -$1.23 | N/A | $103M | $217.65K | N/A | N/A | N/A | ||
| 8/10/20 | |
Q220 | -$0.83 | N/A | N/A | $237K | $135.7K | N/A | | | Details |
| 8/9/22 | Q222 | -$0.39 | -$0.30 | -$0.09 | $272.82K | $529K | N/A | | | Details | |
| 11/8/17 | |
Q317 | -$0.39 | -$0.25 | -$0.14 | $2.6M | $9.36M | = | | | Details |
| 8/9/21 | |
Q221 | -$0.39 | -$0.25 | -$0.14 | $273K | $1.21M | N/A | | | Details |
| 3/12/20 | |
Q419 | -$0.38 | -$0.24 | -$0.14 | $279K | $2.32M | N/A | | | Details |
| 5/10/22 | |
Q122 | -$0.36 | -$0.34 | -$0.02 | $199K | $670K | N/A | | | Details |
